VERTEX PHARMACEUTICALS INC MA (VRTX)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenues | 2,964,700 | 2,770,200 | 2,771,900 | 2,645,600 |
| Selling, general and administrative expenses | 424,600 | 396,400 | 371,800 | 372,200 |
| Research and development expenses | 978,400 | 979,700 | 875,900 | 966,600 |
| Acquired in-process research and development expenses | 2,200 | 19,800 | 15,000 | 4,449,100 |
| Intangible asset impairment charge | - | 379,000 | - | - |
| Cost of sales | 407,500 | 363,000 | 392,600 | 371,900 |
| Change in fair value of contingent consideration | 900 | 2,200 | 300 | 500 |
| Total costs and expenses | 1,813,600 | 2,140,100 | 1,655,600 | 6,160,300 |
| Income (loss) from operations | 1,151,100 | 630,100 | 1,116,300 | -3,514,700 |
| Interest income | 122,400 | 120,900 | 132,200 | 156,500 |
| Interest expense | 3,700 | 3,000 | 7,500 | 9,900 |
| Other income (expense), net | 13,200 | -17,600 | -16,900 | -23,100 |
| Income (loss) before provision for income taxes | 1,283,000 | 730,400 | 1,224,100 | -3,391,200 |
| Provision for income taxes | 250,100 | 84,100 | 178,700 | 202,400 |
| Net income (loss) | 1,032,900 | 646,300 | 1,045,400 | -3,593,600 |
| Basic (in dollars per share) | 4.02 | 2.52 | 4.05 | -13.92 |
| Basic (in shares) | 256,700,000 | 256,900,000 | 258,000,000 | 258,100,000 |
| Diluted (in dollars per share) | 3.99 | 2.49 | 4.01 | -13.92 |
| Diluted (in shares) | 258,900,000 | 259,500,000 | 261,000,000 | 258,100,000 |